Healthcare entity
regulation is the sole category represented across all 1 tracked stories. EMA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 11 original sources each against 3.1 for the same window.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. EMA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 11 original sources each against 3.1 for the same window. At 8, the average consequence score sits above the same-window beat average of 6.3. Cancer Drug Supply appears in 1 tracked Healthcare story from March 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 34 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cancer Drug Supply. Shared-story counts are live from our verified record — not editorial picks.
Geopolitical conflict has forced a massive rerouting of pharmaceutical trade lanes, specifically endangering the delivery of time-sensitive oncology treatments. As transit times lengthen, industry experts warn of imminent shortages and compromised cold-chain integrity for life-saving medications.
Cancer Drug Supply is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
